Results 191 to 200 of about 15,568 (286)

Molecular genetics of common variable immunodeficiency

, 2017
Bogaert, Delfien, De Baere, Elfride, Dullaers, Melissa, Haerynck, Filomeen   +3 more
core   +1 more source

Orthotopic liver transplantation in the mouse [PDF]

, 1991
Demetris, AJ, Fung, JJ, Ildstad, ST, Qian, S, Starzl, TE   +4 more
core   +2 more sources

Real‐World Effectiveness and Safety of Pegzilarginase Treatment in Arginase 1 Deficiency

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Pegzilarginase is the first disease‐modifying drug for arginase 1 deficiency. In clinical trials, pegzilarginase effectively normalised plasma arginine (pArg), which was associated with clinically relevant improvements in neuromotor outcomes. We report from a French early access scheme the first report on experience from pegzilarginase therapy
Anaïs Brassier, Alina Arion, Jean‐Baptiste Arnoux, Magalie Barth, Dries Dobbelaere, Magali Gorce, Michael Grövdal, Cécile Laroche, Olivia Rime, Manuel Schiff, Mattias Rudebeck   +10 more
wiley   +1 more source

Autoimmune thyroid disease in inborn errors of immunity: a retrospective perspective. [PDF]

Orphanet J Rare Dis
Bayrak Durmaz MS, Ozdel Ozturk B, Gorgulu Akin B, Kalkan F, Soyyiğit S.   +4 more
europepmc   +1 more source

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Thalidomide serves as a molecular nexus linking chemistry and biology: advances in synthesis and structural understanding enable protein degradation technologies, while its immunomodulatory activity underpins anti‐inflammatory and anticancer therapies.
Konstantina Nikovia, Michael Kapsalis, Michael Georgoulakis, Athanasios Panousis, Constantinos G. Neochoritis   +4 more
wiley   +1 more source

Current infectious disease management challenges in inborn errors of immunity. [PDF]

Ann Clin Microbiol Antimicrob
Zheng S, Lowe DM.
europepmc   +1 more source

Advanced Corneal Hydrogels: From Passive Replacement to Active Regeneration and Intelligent Interaction

Advanced Science, Volume 13, Issue 19, 2 April 2026.
This review charts the evolution of corneal hydrogels from passive replacements to active and intelligent systems, evaluating natural and synthetic materials while addressing design challenges such as transparency and strength. Advanced applications such as scarless wound healing, three‐dimensional bioprinting, and smart wearables are highlighted to ...
Xinwei Wang, Wen Zhou, Haotian Xue, Wenjun Xue, Guangping Gao, Bing Zhu, Hongyuan Song, Qingqiang Xu, Jing Zhao, Wei Shen   +9 more
wiley   +1 more source

Exploring the strengths and limitations of AI-driven variant prioritization versus manual curation in inborn errors of immunity. [PDF]

Front Genet
Moushib LI, Moreno-Ruiz N, Martín-Nalda A, Rivière JG, Urban B, Dieli-Crimi R, Perurena-Prieto J, Aguiló-Cucurull A, Pérez-Estévez E, Solanich X, Soler-Palacín P, Colobran R, Batlle-Masó L.   +12 more
europepmc   +1 more source

The Effect of Maternal Pertussis Vaccination on Neonatal Health Outcomes in the Dutch Pregnancy Drug Register

Birth Defects Research, Volume 118, Issue 4, April 2026.
ABSTRACT Background The currently high pertussis‐related morbidity and mortality among infants has led to increased international attention for pertussis vaccination during pregnancy. We studied the safety of maternal pertussis vaccination in the Netherlands with respect to neonatal health. Methods Data from the cohort the Dutch Pregnancy Drug Register
Petra J. Woestenberg, Veronique Y. F. Maas, Maud de Feijter, Leontine van Balveren, Maartje Conijn, Sanne Boetzkes, Anneke J. L. M. Passier, Agnes C. Kant   +7 more
wiley   +1 more source

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objective Immune checkpoint inhibitors (ICIs) combined with platinum‐based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum‐based compounds by using the FAERS database.
Boyi Liu, Wenchao Zhang, Ruizhe Huang, Dinwen Liu, Jiaxing Liu, Ao Han, Yike Li, Danna Chen   +7 more
wiley   +1 more source